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There are several problems associated with
treatment of malaria, especially in sub-Sa-
haran Africa: effectiveness, access (finan-
cial and physical), safety and tolerability,
and adherence. Even in an ideal situation
in which the first 3 factors are not a prob-
lem, adherence would still be problematic,
especially when dealing with rural popu-
lations in developing countries, where re-
lief of symptoms of malaria is often in-
terpreted as “cure” and where there is,
therefore, great reluctance to continue tak-
ing the rest of the medication as pre-
scribed. Adherence has been defined as
“the extent to which a patient fulfills the
intention of the prescriber in taking med-
ication” [1, p. 7]. Several drug-associated
factors may affect adherence [1], including
appropriateness of the prescription, side
effects, dose regimen, drug presentation
and formulation, number of drugs pre-
scribed concurrently, and duration of
treatment.
Adherence to antimalarial drugs has
been shown to be better with effective
treatments, coupled with increased knowl-
edge by the health care professional, better
medication packaging, and provision of
correct dosages [2]. Combination therapy,
especially that which contains artemisinin
derivatives (ACT), is now accepted as the
way forward in confronting the serious
problem of drug-resistant Plasmodium fal-
ciparum malaria [3]. Combination ther-
apy has the potential to improve thera-
peutic effectiveness, delay spread of drug
resistance, and reduce gametocyte carriage
[4]. ACTs need to be given for at least 3
days to maximize the number of parasites
killed. Because adherence is a critical com-
ponent of the overall effectiveness of a
drug [5], complicated dose regimens are
bound to compromise effectiveness
through reduced adherence. The simplest
ideal dose regimen for ACTs would in-
volve once-daily administration for at least
3 days. A few studies have reported on the
efficacy of and/or adherence to such
“once-daily” ACTs, but some of the results
are conflicting. For example, one study of
a relatively simple regimen (a single dose
of sulfadoxine [equivalent to 25 mg per
kilogram of body weight] on the first day,
and 4 mg of artesunate per kilogram of
body weight daily for 3 days) that was
performed in a refugee camp in Zambia
reported that up to 50% of the patients
were nonadherent [6]. In a separate study
performed in the same camp, the authors
reported a significant difference in ther-
apeutic response to the same combination
between patients who received either su-
pervised or unsupervised treatment, a fact
attributed to insufficient patient adher-
ence in the unsupervised group [7]. In
contrast, in another study, 90% of patients
in southwestern Uganda were reported to
be adherent to the more complicated 6-
dose regimen of artemether-lumefantrine
for treatment of uncomplicated malaria
[8]. There is need for more comparative
studies on the efficacy of and adherence
to simple regimens of ACTs for treatment
of uncomplicated malaria.
In this issue of Clinical Infectious Dis-
eases, Ashley et al. [9] describe the results
of a randomized trial comparing a simple,
once-daily dose of dihydroartemisinin-pi-
peraquine administered over 3 days (DP3)
with the standard but more complicated
regimen of an equivalent total dose of the
same combination given in 4 doses over
3 days (DP4) and with a once-daily dose
of mefloquine-artesunate administered
over 3 days (MAS3) for the treatment of
multidrug-resistant falciparum malaria.
Fever and parasite clearance rates were
similar for the 3 regimens, whereas PCR
genotyping–adjusted cure rates were
99.4%, 100%, and 95.7% for the DP3,
DP4, and MAS3 groups, respectively, 63
days after starting therapy. Given the level
of parasite resistance in the study area, the
results with DP3 are encouraging. This
simple regimen could even be used in sit-
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problematic. For example, the first dose
on day 0 could be administered under su-
pervision at the health facility, and even
the patients who are most likely to be non-
compliant would presumably adhere to
the 2 doses remaining in the regimen.
Although malaria transmission rates
vary widely in sub-Saharan Africa, the ma-
jority of susceptible people live in areas
with rates that are higher than that in
Southeast Asia. For example, the ento-
mological inoculation rate (EIR), which
measures the number of infective mos-
quito bites per person per period, has been
reported to be 0.3 infective bites/person
per year in Tak Province, Thailand [10].
In contrast, in some parts of Africa, the
EIR has been estimated to range from
0.001 to 2.7 infective bites/person per
night [11, 12]. This factor, plus the dif-
ferences in the level of parasite resistance
between Southeast Asia and sub-Saharan
Africa, makes it difficult to interpret the
results presented by Ashley and colleagues
in the context of potential use of the DP3
regimen in sub-Saharan Africa and other
areas with different malaria ecologies.
Thus, although the results reported by
Ashley et al. [9] are encouraging, there is
a need to perform similar trials of DP3
and other “once-daily” regimens, espe-
cially in sub-Saharan Africa. Such trials
would be especially timely, given that sev-
eral countries in sub-Saharan Africa have
switched or are in the process of switching
to Coartem (artemether-lumefantrine;
Novartis) as the recommended first-line
treatment for uncomplicated malaria. The
treatment regimen with this drug is more
complicated and, presumably, will be as-
sociated with more problems of adherence
than equally effective but simpler “once-
daily” regimens. Taken together with re-
sults presented by Ashley and colleagues,
the results of similar studies in sub-Sa-
haran Africa will help clarify whether these
simple, once-daily, 3-day regimens are the
way forward in the treatment of uncom-
plicated malaria.
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